Neurogene, Inc. (NGNE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$38.60+2.63%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NGNE
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||
| Revenues | — | — | 0.9 | 0.0 | — | — | — | 25.0 | 25.0 | — | — | — | — |
| Operating Expenses & Income | |||||||||||||
| R&D Expenses | 88.5 | 75.0 | 60.9 | 44.4 | 47.5 | 39.2 | — | — | 41.8 | 36.3 | 28.4 | 15.8 | 18.1 |
| Operating Income | (121.3) | (103.3) | (82.6) | (55.6) | (56.5) | (60.7) | (33.7) | (71.0) | (32.6) | (50.2) | (37.0) | (21.9) | (24.0) |
| Earnings from Continuing Operations | |||||||||||||
| Interest Expense | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — | 0.5 |
| Interest & Investment Income | 9.7 | 11.5 | 8.5 | 3.0 | 1.3 | — | — | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | (2.9) | (1.3) | — | — | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | — | 13.0 | — | — | (0.0) | (0.0) | 0.5 | 1.5 | 1.0 | 0.9 | 0.6 | (0.5) | (1.7) |
| Asset Writedown | — | 0.1 | 0.1 | 0.0 | — | — | — | — | — | — | — | 0.0 | 0.0 |
| EBT, Incl. Unusual Items | — | (90.4) | (75.1) | (36.3) | (55.2) | (60.7) | (33.3) | (69.4) | (31.6) | (50.2) | (37.0) | (21.9) | (24.0) |
| Income Tax Expense | — | — | — | — | — | — | — | — | — | — | 0.0 | (0.0) | 0.0 |
| Net Income | |||||||||||||
| Net Income | (111.1) | (90.4) | (75.1) | (36.3) | (55.2) | (60.7) | (33.3) | (69.4) | (31.6) | (50.2) | (37.0) | (21.9) | (24.0) |
| Per Share | |||||||||||||
| Basic EPS | (4.93) | (4.24) | (4.28) | — | (1.04) | (1.10) | (0.64) | — | — | — | — | — | — |
| Diluted EPS | (4.93) | (4.24) | (4.28) | — | (1.04) | (1.10) | (0.64) | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 22.6 | 21.3 | 17.6 | — | 55.2 | 55.0 | 51.8 | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 22.6 | 21.3 | 17.6 | — | 55.2 | 55.0 | 51.8 | — | — | — | — | — | — |
| Supplemental | |||||||||||||
| EBITDA | — | (100.3) | (79.4) | (52.3) | (53.3) | (59.4) | (32.9) | (70.6) | — | — | — | — | (23.9) |
| EBIT | (121.3) | (103.3) | (82.6) | (55.6) | (56.5) | (60.7) | (33.7) | (71.0) | (32.6) | (50.2) | (37.0) | (21.9) | (24.0) |
| Effective Tax Rate | — | — | — | — | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.